About Us

We are a healthcare company at the intersection of diagnostics and consumer tech

Founders

Truvian was founded by a series of tech and life sciences entrepreneurs

Well Funded

Truvian has raised $46.2M to date from top tier investors including GreatPoint Ventures and Domain Associates

Located in San Diego

TruHQ is a state-of-the-art R&D and manufacturing facility located in San Diego CA

Exceptional Team

Team comprises 50+ employees includes management team with proven track record of success in diagnostics

Easy Check COVID-19 IgM/IgG™
Performance Data Summary

- Incorporates both nucleocapsid and spike RBD antigens
- Performance Data from Internal and External Validation:
  - **Sensitivity:** 63/64 (98.44%) of COVID+ confirmed by PCR were positive
  - **Specificity:** 180/182 (98.90%) of pre-covid samples were negative
  - **Cross Reactivity:** 0/87 (0%) of “other viruses” samples were positive
  - **Concordance with lab-based serology instrument**: 124/126 (98.4%) samples concordant with Roche Total Ab test

Easy Check COVID-19 IgM/IgG™
Sensitivity and Specificity Data

Normal donors were from samples collected “pre-covid” (prior to Sept 2019) or confirmed PCR-negative. Patient samples were confirmed positive via RT-PCR and > 14 days post onset of symptoms.

		Comparator (RT-PCR)		
		Positive	Negative	Total
Positive	IgG+/IgM+	56	0	56
	IgG+/IgM-	6	1	7
	IgG-/IgM+	1	1	2
Negative	IgG-/IgM-	1	180	181
Subtotal		64	182	246

Positive Percent Agreement (PPA): 63/64 = **98.44%** (95% CI: 91.7%-99.7%)
Negative Percent Agreement (NPA): 180/182 = **98.90%** (95% CI: 96.1% - 99.7%)

Easy Check COVID-19 IgM/IgG™

National Cancer Institute (NCI) Validation Data

Measure	Estimate	Confidence Interval
Combined Sensitivity	100% (30/30)	88.7%; 100%
Combined Specificity	97.5% (78/80)	91.3%; 99.3%
Cross-reactivity with HIV+	0.0% (0/10), not detected	-

Easy Check COVID-19 IgM/IgG™

Cross-Reactivity Data

We tested 87 patient samples were confirmed positive for infectious diseases (including non COVID19 coronaviruses). None cross-reacted with Truvian's test.

Virus Type	Total Patients Tested	# Positive
Anti-Influenza A	5	0
Anti-Influenza B	5	0
Anti-HCV	10	0
Anti-HBV	5	0
Anti-229E (alpha coronavirus)	3	0
Anti-NL63 (alpha coronavirus)	7	0
Anti-OC43 (beta coronavirus)	9	0
Anti-HKU1 (beta coronavirus)	5	0
Antinuclear antibodies (ANA)	5	0
Anti-respiratory syncytial virus	6	0
Anti-HIV	10	0
Anti-Dengue virus	5	0
Anti-Syphilis	5	0
Anti-Rhinovirus	2	0
Anti-Hepatitis B	5	0
Total N	87	0

Easy Check COVID-19 IgM/IgG™
Concordance with Roche Elecsys (10Min)

High concordance demonstrated with Roche's total Ab test – 124/126 (98.4%) are concordant

Patients with infectious disease (non-COVID19)

		Roche	
		Antibody Positive	**Antibody Negative**
Truvian	**Antibody Positive**	0	0
	Antibody Negative	0	41
	% Concodordant	**41/41**	**100.0%**

Patients with COVID19

		Roche	
		Antibody Positive	**Antibody Negative**
Truvian	**Antibody Positive**	76	2
	Antibody Negative	0	7
	% Concodordant	**83/85**	**97.6%**

Collaboration Partners

THE UNIVERSITY OF CHICAGO

UC San Diego

70 San Diego Blood Bank Years of Saving Lives 1950-2020

Additional Partners Forthcoming